DOJ: Roxane Bilked Medicare, Medicaid
Boehringer Ingelheim Roxane Inc. is accused of reporting fraudulent prices for several pharmaceutical products, knowing that federal health care programs establish reimbursement rates based on those reported prices. Medicare and Medicaid have reimbursed Roxane’s customers more than $500 million for the pharmaceutical company’s generic drugs, the DOJ said.
The DOJ, which joined the lawsuit Monday,...
To view the full article, register now.